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The 2016 European Guidelines on cardiovascular disease prevention (CVD) represented an 
evidence-based consensus of the Sixth European Joint Task Force (JTF) involving 10 
professional societies, where the evidence and knowledge gaps in managing CVD 
prevention were revised. In addition, the guidelines provided tools for healthcare 
professionals to promote population-based strategies and integrate these into national or 
regional prevention frameworks and to translate these in locally delivered healthcare 
services, in line with the recommendations of the World Health Organization (WHO) global 
status report on non-communicable diseases 2010 1. 
For the present document, components from the 6th JTF and experts from the European 
Association of Preventive Cardiology (EAPC) of the European Society of Cardiology (ESC) 
were invited to provide a summary and critical review of the most important new studies 
and evidence since the 2016 Guidelines were published. 
The structure of the document follows that of the previous Guidelines and has four parts: 1. 
Introduction (epidemiology and cost effectiveness); 2. Cardiovascular (CV) risk; 3. How to 
intervene? (at population level, at individual level, and in specific diseases); 4. The settings: 
where to intervene?  
In keeping with the 2016 Guidelines, greater emphasis has been put on a population-based 
approach, and on disease-specific interventions. Finally, the presence several gaps in 
knowledge is highlighted.  
 
1.1 Epidemiology  
 
According to the latest (2017) European data from the ESC Atlas, CVD accounts for 45% of 
all deaths in Europe and 37% of all deaths in the European Union (EU) and thus remains one 
of the most common disorders2. There were ~83.5 million people living with CVD in ESC 
member countries in 2015. The prevalence was driven predominantly by peripheral vascular 
disease (~35.7 million), followed by ischemic heart disease (IHD) (~29.4 million), other CVD 
such as pericardial disease, valvular heart disease (~13.3 million), atrial fibrillation (AF) (~9.5 
million) and stroke (~7.5 million). Moreover, the economic status with the differences in 
gross domestic product (GDP) in each country plays a critical role. Age-standardized 
prevalent cases of CVD per 100 000 people in high- and middle- income countries were 5093 
and 6570 for women compared with 6563 and 8358 for men. IHD was less prevalent in high-
income compared with middle-income countries in women (1212 vs. 2212) and men (2267 vs. 
3788). Stroke prevalence showed similar inequality between high- and middle-income 
countries in women (448 vs. 843) and men (497 vs. 863). This reflects not only population 
growth and ageing, because age-standardized data for men and women show consistent 
declines in CVD prevalence across high-income ESC member countries during the last 25 
years. Instead half of the middle-income countries recorded an increase in disease 
prevalence, with the inequalities in disease burden being further emphasized by a greater 
than two-fold excess of disability-adjusted life years (DALY) lost to IHD in middle-income 
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compared with high-income ESC member countries: in women and men, there were a mean 
of 1004 and 2407 age-standardized DALYs per 100 000 people lost during 2015 in high-
income member countries compared with 2715 and 5977 in middle-income member 
countries.  
 
Similarly for incidence, out of more than 11 million new cases of CVD in the 47 ESC member 
countries in 2015, larger increases were observed in middle-income countries in both women 
and men (by 17% and 26% respectively) vs high-income countries (by 11% and 22% 
respectively). 
Higher prevalence of CVD risk factors, such as obesity, diabetes mellitus (DM), age-
standardized raised blood pressure (BP), and smoking  in middle-income countries are likely 
to have contributed to the higher CV mortality 2. For example, the average prevalence of age-
standardized raised BP in women and men was 18.3% and 27.3% in high-income ESC 
member countries and 23.5% and 30.3% in middle-income countries. 
This presents the middle-income member countries of the ESC with a clear economic 
imperative to develop policies to protect their populations against the development and 
progression of CVD. Prevalence statistics are not always closely associated with GDP. Thus, 
the commitment to the cause of tackling CVD is not simply a question of resources but also 
requires sound health policies that are backed up by implementation strategies.  
 
1.2 Cost effectiveness 
How to reduce CVD costs is an increasingly pressing question for low- and middle-income 
countries. In primary prevention, across all age ranges, targeted case finding using a prior 
estimate of CVD risk is more efficient than universal case finding in healthy adults, which 
supports the implementation of validated risk scores.3 A small case-based training program 
for general practitioners in the Stockholm County, aimed to implement evidence-based care 
of patients at very high risk of coronary death, was associated with decreased mortality and 
showed long-term cost-effectiveness4. 
In an extra European country (India) a microsimulation model of myocardial infarction (MI) 
and stroke has demonstrated the efficacy and the cost-effectiveness of expanding national 




2. CARDIOVASCULAR RISK 
2.1 Risk stratification and scores 
2.1.1 Non-traditional CVD risk factors.  
Non-traditional risk factors are considered potentially useful if 1) improve risk classification, 
2) there was no evidence of substantial publication bias and 3) their measurement is likely to 
be cost-effective. Consequently, socio-economic status, family history, (central) obesity, 
coronary artery calcium scoring (CAC), carotid plaque, abnormal ankle-brachial index (ABI) 
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have been considered potentially useful risk modifiers of the SCORE 1. In 2018, the US 
Preventive Services Task Force updated its 2009 and 2013 recommendations by providing a 
novel evidence report and systematic review.6 They concluded that ABI, CAC, and high-
sensitivity C-reactive protein (hsCRP) can improve discrimination and reclassification with 
respect to conventional risk score, but that such improvements were generally small and that 
the literature was insufficient to draw firm conclusions on their added value 6. 
The 2019 American College of Cardiology/American Heart Association (ACC/AHA) 
Guideline on the Primary Prevention of CVD, which considers 10-year risk estimation, takes 
a relatively liberal position, in that many ‗risk enhancing factors‘ are recommended (Class 
IIa) to guide decision making in borderline (5% to <7.5%) and intermediate (7.5% to <20%) 
risk groups 7. These include, amongst others, family history, ethnicity, metabolic syndrome 
criteria, renal function, hsCRP, lipoprotein(a) (Lp(a)), apolipoprotein B (apoB), ABI, history 
of pregnancy-associated conditions or premature menopause, and chronic inflammatory 
disease. The US guideline apparently fails to account for the substantial level of publication 
bias in this field 8 and does not make explicit that a favourable profile of these ‗risk enhancers‘ 
would lower an individual‘s risk considerably. A separate class IIa recommendation was 
issued regarding the use of CAC in some patients at borderline and all patients at 
intermediate risk. This approach seems more aggressive than the 2016 ESC guideline, which 
only has a class IIb recommendation to consider CAC around decisional thresholds 1. Taken 
together, relatively little new evidence has emerged regarding the added value of many 
suggested biomarkers and other risk modifiers. Key questions regarding evidence, cost-
effectiveness and potential harm of larger-scale use of CAC scoring for refinement of risk 
stratification remain.  
Future interest in the wider use of cardiac biomarkers (i.e. natriuretic peptide and cardiac 
troponin blood concentration) is rising due to emerging promising data 9,10 but further work 
is needed. 
 
2.1.2 Which Risk Score? 
There is debate about the optimum algorithm for CVD risk estimation. Although the 
Systematic COronary Risk Evaluation (SCORE) risk engine is generally recommended in the 
current ESC guideline, the use of any risk score is encouraged, if such risk score was 
developed in a methodologically sound manner and are optimally calibrated for use in 
particular countries or geographical regions 11, such as Q-RISK/JBS3 of people in the United 
Kingdom 12.  
However, the need for a revaluation with recalibration of the current risk scores has been 
underlined. A head-to-head comparison of four algorithms (Framingham risk score, SCORE, 
pooled cohort equations, and Reynolds risk score) recommended by primary prevention 
guidelines have shown wide differences in clinical performances. These differences were 
reduced after ‗recalibration‘, using the risk factor profile and CVD incidence of target 
populations. It was estimated that to prevent one CVD event, it would be necessary to 
initiate statin therapy in 44–51 such individuals using original algorithms, in contrast to 37–
39 individuals with recalibrated algorithms 11. 
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Furthermore, two other important issues regarding risk assessment are subject to current 
debate. 
First, the question of whether risk stratification for people with previous CVD events may be 
appropriate remains unanswered. Risk among such persons is heterogeneous and with the 
introduction of very costly interventions (such as proprotein convertase subtilisin/kexin 
type 9 [PCSK9] inhibitors), further risk stratification in secondary prevention may become 
necessary. Some models have already been developed, and suggest that predictors of risk 
may be quite different from primary prevention13,14. 
A second interesting development is to adopt a lifetime perspective on CVD risk assessment. 
Although this was already touched upon in the 2016 ESC guideline, and is also part of the 
2019 US guideline 7, there is no consensus as to which level of lifetime risk and at which 
particular age this risk is calculated should trigger treatment recommendations. An 
extension of this lifetime risk perspective is to calculate lifetime benefit from the initiation of 
CV preventive drugs. This perspective may be more intuitive to patients facing a decision 
whether or not to start preventive drug treatment. Models have been developed to calculate 
(disease-free) life-years gained for both for populations of people with and without DM 15,16. 
For the time being, such alternative perspectives primarily facilitate communication with 
patients about treatment decisions, but if further studies validate this approach, life-time 
(disease-free) gained could become a more central criterion in formal treatment 
recommendations and in supporting the importance of even moderate reduction in CV risk. 
 
2.2 Other risk markers   
2.2.1 Genetics and Epigenetics 
There has been a significant increase in the number of epidemiological studies investigating 
CV risk factors and outcomes in relation to DNA methylation, histone modifications, RNA-
based mechanisms but many gaps remain in our understanding of the underlying cause and 
biological implications. An association between coronary artery disease (CAD)  presence and 
characteristics and selected circulating transcriptional and epigenetic-sensitive biomarkers 
linked to cholesterol pathway has been observed 17.  
A polygenic risk score derived from up to 57 common DNA sequence variants previously 
associated with CAD 18 has allowed to identify individuals with a greater burden of 
subclinical atherosclerosis and would derive a greater relative and absolute benefit from 
statin therapy to prevent a first CAD event 19.  
It is noteworthy that there is still no evidence of cost-effectiveness of application of CV 
genetic risk score testing in clinical practice, such as targeting statin therapy in individuals at 
low-to-moderate CV risk 20. 
2.2.2 Psychosocial 
The EUROASPIRE IV survey21 confirmed the high prevalence of symptoms of depression 
and anxiety in patients with CAD (22,4% and 26,3%, respectively). Both symptoms were 
more prevalent in women than men (30,6% vs. 19,8%, and 39,4% vs. 22,1%, respectively), and 
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were associated with lower educational level and more sedentary lifestyle. Furthermore, 
depression was associated with current smoking, central obesity and DM. 
The ESC position paper on depression and CAD 22 confirmed the relevance of depressive 
symptoms for CAD incidence and prognosis, and summarized pathophysiological 
mechanisms like poor and sedentary lifestyles, neurohumoral activation, inflammation and 
endothelial dysfunction, that promote coronary atherosclerosis and microvascular 
remodeling. Thus, depression may trigger more intensive efforts to detect and manage risk 
factors. Whether treating depression per se improves outlook remains unclear. 
With respect to the ESC guideline regarding the clinical interview 1, a validation study has 
shown only moderate to fair correlations of the screening items with established 
psychometric questionnaires 23. Hence, refinement of the screening items is required. 
As adverse experiences in childhood and adolescence, such as psychological, physical, or 
sexual abuse in the child and substance abuse of family members, are associated with worse 
cardiometabolic outcomes in adults, a position statement of the AHA 24 recommended the 
development of early interventions to ameliorate these harmful exposures.  
In the recent update on QRISK score [https://qrisk.org/three] having severe mental illnesses 
(i.e. schizophrenia, bipolar disorder and moderate/severe depression) leads to meaningful 
risk reclassification25. 
2.2.3 Imaging Methods  
In patients with intermediate or borderline cardiovascular risk, CAC measurement based on 
computed tomography (CT) can reclassify risk upward (particularly if the score is ≥100 
Agatston units or ≥75th age/sex/race percentile) or downward (if CAC is zero and it is now 
a IIa recommendation in the ACC/AHA  guidelines) in risk stratification7.  
However, while the amount of CAC roughly correlates with the total amount of 
atherosclerosis present in the coronary arteries, it correlates poorly with the degree of 
luminal narrowing. Furthermore, it does not provide direct information about the total 
plaque burden or stenosis severity and can be absent in middle-aged patients with soft non-
calcified plaque.  
In the randomized open-label, SCOT-HEART trial 26  in patients with stable chest pain, the 
use of CT coronary angiography on top of standard of care (with consequent changes in 
treatment) reduced the rate of death from CAD or nonfatal MI (hazard ratio [HR] 0.59; 95% 
confidence interval [CI], 0.41 to 0.84; P=0.004), compared with standard care alone. This 
difference was driven primarily by a lower rate of nonfatal MI. The reductions in coronary 
events were the same irrespective of symptoms, independent of baseline statin use or 
cardiovascular risk score. These findings suggest that using a cardiovascular risk score both 
over and under treats individuals, and that CT coronary angiography appears to be 
associated with better reductions in coronary events irrespective of the risk score. The 
reasons for the benefits of CT coronary angiography might be related to better targeted 
secondary prevention, closer adherence to lifestyle modifications and preventative therapies, 
and coronary revascularisation in those with prognostically significant disease.  
 10 
Currently, the use of CT coronary angiography as a risk stratification tool in asymptomatic 
individuals is not supported by data since no prospective, randomized intervention studies 
have been performed. 
 
2.3 Clinical conditions affecting CV risk 
2.3.1 Diabetes Mellitus 
One group that can benefit from earlier identification are subjects with undiagnosed DM.  
Screening for DM in individuals identified as high risk by validated DM risk scores applied 
to electronic primary care data is feasible and can result in more intensive treatment of CVD 
risk factors and reduction in CVD risk27,28.  Patients who lost > 5% body weight at one year 
after diagnosis of DM had a 48% lower 10 year adjusted hazard of CVD incidence compared 
to maintained weight27. Weight loss can also result in remission of DM as shown in the 
DIRECT trial in primary care randomising people with overweight/obesity and type 2 DM 
diagnosed in the last 6 years to a diet replacement programme or usual care. In the 
intervention group, 24% achieved a weight loss of ≥ 15 kg, 46% had DM remission, 
compared to 0% and 4% of the usual care group at one year. The amount of weight loss was 
associated with DM remission, as 86% of those who lost > 15 kg achieved remission in the 
first year compared to 34% of those with 5 – 10 kg weight loss29. 
Whilst most guidelines prioritize the use of intensive risk factor management in people with 
type 2 DM above the age of 40, as do the 2016 ESC CVD prevention guidelines1, recent 
research has better highlighted the importance of age of onset as a predictor of life years lost 
from DM. There is now clear evidence that younger onset type 2 DM leads to considerably 
greater losses and excess CVD outcomes, such that those developing Type 2 under the age of 
20 can lose well over a decade in life years whereas there may be negligible loss of life when 
DM develops after the age of 80 years of age 30.  These findings should help to better focus on 
CVD risk factor management in those developing DM under the age of 40, though caution 
with the use of statins and some antihypertensive agents remains important for women of 
childbearing age.  Similarly, recent evidence suggests that age of onset also matters to those 
with Type 1 DM because associated with greater loss of life expectancy 31.  There is some 
evidence that people with type 1 DM have greater excess and absolute risks for CAD and 
heart failure (HF) than those with type 2 DM 32 and thus there may be longer-term benefits 
from more aggressive use of statins and BP control.   
 
2.3.2 Chronic kidney disease  
Chronic kidney disease is a recognized as a marker for future CVD events. In the recent 
update on QRISK score [https://qrisk.org/three] having chronic kidney disease (stage 3-4-5) 




An association between acute respiratory infections, especially those occurring at times of 
peak influenza virus circulation, and acute MI has been reported by  observational studies. 
33,34 
A self-controlled case-series design to evaluate the association between laboratory-confirmed 
influenza infection and hospitalization for MI showed that the incidence of admissions for 
MI was six times as high during the 7 days after laboratory confirmation of influenza 
infection vs. control interval (20.0 admissions per week vs. 3.3 admissions per week). The 
incidence ratio point estimates were highest for older adults, for patients with influenza B 
infection, and for patients who had their first MI. 35    
The recommendation on influenza vaccination on secondary prevention in patients with 
CVD is supported by new evidences. A Cochrane review of 8 randomized clinical trials in 
12,029 patients with CVD 36 reported a significant reduction in CV mortality among patients 
vaccinated against influenza (RR 0.44, 95% CI 0.26-0.76).  
Strong evidences of the effectiveness of influenza vaccination in primary prevention of CVD 
are still lacking. 
 
2.3.4 Periodontitis 
Most published studies have found a positive association between periodontitis and CVD 37. 
A cross-sectional analysis of a cohort of 60,174 participants 38 showed that periodontitis was 
independently associated with atherosclerotic CVD (OR 1.59 ,95% CI 1.39-1.81). A 
nationwide cohort of 17,691 patients who received a hospital diagnosis of periodontitis 
within a 15-year period and matched them with 83,003 controls from the general population 
found an increased risk for CV death (OR 2.02; 95% CI 1.87 to 2.18) and for all-cause 
mortality (OR 2.70; 95% CI 2.60 to 2.81). 39 A meta-analysis of observational studies including 
22 observational studies including 129,630 participants showed that patients with 
periodontitis have increased risk of MI (OR 2.02; 95% CI 1.59-2.57). 40 
A systematic review to investigate the effects of periodontal therapy in preventing the 
occurrence of, and management or recurrence of, CVD in patients with chronic periodontitis 
41 found very low quality evidence that was insufficient to support or refute whether 
periodontal therapy can prevent the recurrence of CVD in the long term in patients with 
chronic periodontitis. No evidence on primary prevention was found. 
 
2.3.5 Cancer 
Several systemic review and meta-analyses are available on the benefit of exercise training 
program in attenuating the reductions in exercise tolerance42 and in improving outcome43. 
Regarding early detection of cardiac injury, exercise cardiac magnetic resonance imaging has 
been shown to be a more sensitive marker of cardiotoxicity than the current standard of care 
tools to assess resting left ventricular ejection fraction in breast cancer patients.44 Also, the 
use of biomarkers has emerged as a valuable tool for the early identification and monitoring 
of cardiotoxicity. In particular, cardiac troponin and B-type natriuretic peptide (BNP) 
elevation during chemotherapy allows identification of patients more prone to develop 
myocardial dysfunction and cardiac events 45. 
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2.3.6 Autoimmune disease 
The assessment of risk factor profile is warranted in adults with inflammatory autoimmune 
disorders. The current guideline1 draws attention to increased CVD risk in auto-immune 
disease, particularly rheumatoid arthritis (RA), but potentially all auto-immune diseases are 
associated with systemic inflammation increased risk: e.g. there is emerging evidence that 
connective tissue disease and, to a somewhat lesser degree, inflammatory bowel disease are 
associated with increased CV risk.46 
In 2017, the European League Against Rheumatism (EULAR) updated its CVD risk 
management guideline,47  but this is now being updated again. The evidence supporting 
increased CVD risk has strengthened, and related to both traditional and non-traditional risk 
factors, the latter including inflammatory activity, clinical disease phenotype, and serum 
antibody profile. Based on recent evidence, EULAR has widened their recommendation for 
CVD risk management to all types of inflammatory joint disease, although the evidence 
remains strongest for RA. Their recommendation is to use CVD risk prediction models in 
these patients and multiply risk estimates by 1.5, even though this multiplication factor is 
uncertain and critically depends on disease phenotype and activity.  
That noted, RA was associated with a higher independent HR for CVD outcomes in QRISK3 
of around 1.2 to 1.3, but this may be because oral steroids was also a strong independent risk 
factor for incident CVD, suggesting (though not providing) some of the risk previously 
associated with CVD in RA, may have been mediated by steroids, or else steroids may reflect 
disease severity25.  
 
2.3.7 Sleep apnoea 
Epidemiological research indicates that obstructive sleep apnoea (OSA) is associated with 
increases in the incidence and progression of CAD, heart failure (HF), stroke and AF. 48 
Central sleep apnea associated with Cheyne-Stokes Respiration (CSA-CSR) predicts incident 
HF and AF; among patients with HF, CSA-CSR strongly predicts mortality. Thus, OSA and 
CSA-CSR are potentially modifiable risk factors for CVD. Treatment of OSA is generally 
reserved for those individuals with an apnoea–hypopnea index (AHI; the number of apnoeas 
and hypopnoeas observed per hour) ≥5 in patients with either signs/symptoms of sleep 
apnoea or associated medical conditions (including hypertension, HF, CAD, significant 
arrhythmias, and other forms of CVD). Alternatively, an AHI ≥15 is treated as OSA, even in 
the absence of signs, symptoms, or associated medical conditions 49.   
Treatment of OSA with continuous positive airway pressure (CPAP) may improve patient-
reported outcomes such as sleepiness, quality of life and mood, but evidences in primary 
prevention of CV disease with CPAP is limited to small studies, with surrogate endpoints, 
combined endpoints and observational data 48. Furthermore, adherence to CPAP seems a 
critical issue, and a potential role for oral appliances (mandibular advancement devices) has 
been put forward 50. 
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2.3.8 Erectile dysfunction 
Erectile dysfunction (ED) is often associated with CAD.51 The third Princeton Consensus 
Conference 52 recommends assessing CV risk in all patients with ED and CVD to estimating 
the risk of mortality and morbidity, associated with sexual activity and advocates lifestyle 
changes 53: these measures are likely to reduce CV risk and improve erectile function. 
Notably ED features as a new independent risk factor for CVD in QRISK3.25 
 
2.3.9 Migraine 
Migraine headache, especially migraine with aura, has been linked to cerebral 
hypoperfusion, systemic vasculopathy, endothelial dysfunction and a hypercoagulable state: 
these factors may increase the risk of various adverse CV and cerebrovascular events 54. A 
meta-analysis of 16 cohort studies, which included 394,942 migraineurs and 757,465 non-
migraineurs has shown that migraine was associated with a higher risk of major adverse CV 
and cerebrovascular event (adjusted HR 1.42, P<0.001), driven by a higher risk of stroke and 
MI. There was no difference in the risk of all-cause mortality 55. 
 
2.4 Other relevant groups 
2.4.3 Young 
A large body of data suggests that younger adults (i.e. <40 years of age) tend to develop an 
increasingly unhealthy CV risk profile, especially in terms of an increased prevalence of 
being overweight or obese, increasing rates of DM, substance abuse, and electronic cigarette 
(e-cig) smoking over the past two decades.56  
Obesity has been identified as the major risk factor to address for the successful prevention 
of CVD and associated mortality. Substance abuse such as opioids, cocaine and anabolic 
steroids has increased among young adults in the past decades that is likely to carry adverse 
risks of future CV events, particularly among those from a low socioeconomic background. 56 
In young adults, very high levels of circulating LDL cholesterol are often attributable to 
familial hypercholesterolemia. By use of the modified Dutch Lipid Clinic Network criteria, 
which are based on nongenetic data, familial hypercholesterolemia is predicted to affect 
approximately 1 in 130–250 individuals worldwide; however, this condition is thought to be 
severely underdiagnosed in most countries 57. 
The continuous relationship between BP and risk of events has been shown at all ages and in 
all ethnic groups. Diastolic BP appears to be a better predictor of events than systolic BP in 
younger (<50 years) vs. older patients. Diastolic BP  tends to decline from midlife as a 
consequence of arterial stiffening; consequently, systolic BP assumes even greater 
importance as a risk factor from midlife 58.  
Masked hypertension is associated with higher CV risk59 and is more common in younger 
people than in older ones, associated with male sex, smoking habit, and higher levels of 
alcohol consumption, anxiety, physical and job stress58.  
On the other side, physical activity ‗per se‘ in young athletes play an hypotensive role with 
respect to normal control 60,61.  
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The presence of organ damage in younger hypertensive patients with grade 1 hypertension 
classified as low risk according to the SCORE system provides unequivocal evidence of 
hypertension-mediated damage and indicates a clear need for BP lowering treatment 58. The 
recent ESC Guidelines recommend that in younger patients with hypertension treated with 
BP-lowering medication, office BP should be reduced to < 130/80 mmHg if treatment is well 
tolerated 58. 
Further studies are warranted to improve our understanding of the magnitude of the 
problem of CVD in young adults and to elucidate treatable risk factors that underlie the 
observed increasing rates of CVDs in this population.  
 
2.4.1 Aging 
Management of CV risk factors in the elderly (>65 years of age) should be followed with 
caution and common sense, adverse effects should be monitored closely, and treatment 
should be reconsidered periodically. Moreover, individuals older than 75 years are 
biologically a very heterogeneous group with frequent frailty, comorbid conditions, and 
multiple concomitant drugs. All these, as well as personal preferences, must be taken into 
account in treatment decisions.  
A prospective cohort study of subjects aged 80 years and older 62 found that CV risk factors 
were not associated with mortality (such as body mass index [BMI], levels of total cholesterol 
and LDLc, current or prior smoking habit), while the presence of frailty was a strong risk 
factor for all-cause mortality (HR: 2.5, 95% CI 1.9–3.2), and for CV mortality (HR: 2.2, 95% CI 
1.4–3.4).   The optimal target BP may be higher among older treated hypertensive patients 
than among middle-aged. In addition, among frail or multimorbid older individuals, a 
relatively low BP may be associated with worse outcomes, and antihypertensive treatment 
may cause more harm than benefit 63.  
Care should be individualized in older diabetic adults, and glycaemic targets suggested by 
guidelines are considered too tight for frail older individuals 64. Management of DM in older 
adults should be adjusted for frailty status, with the intention of reducing complications and 
improving quality of life 65.  
The decision to initiate primary prevention with statins in people older than 75 years of age 
cannot be based directly on randomised clinical trials evidence 66.  
A meta-analysis of data from all large statin trials to compare the effects of statin therapy at 
different ages showed significant reductions in major vascular events irrespective of age, but 
there is less direct evidence of benefit among patients older than 75 years who do not already 
have evidence of occlusive vascular disease 67. Thus, limited evidence is available on therapy 
for primary prevention of CVDs in very elderly and frail individuals.   
 
2.4.4 Women  
It is generally held that women are at lower risk of CVD than men, but this is misleading. 
Ultimately more women than men die of CVD in Europe, but at an older age. Inspection of 
the SCORE charts suggests that risk is deferred by about 10 years. The ESC guideline1 
emphasises the increased risk of the development of sustained hypertension and/or DM in 
women who have had obstetric complications including pre-eclampsia, pregnancy-related 
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hypertension, and gestational DM. The degree to which CVD risk is elevated independent 
from these risk factors was less certain. Moreover, pregnancy complications, such pre-
eclampsia, also increases the CV risk of the offspring, and not only of the mother 68.  
Lifestyle (before conception) of the future mother and father can (by epigenetic mechanisms) 
influence the possibility to have an healthy child 69. 
Although the evidence has been strengthened and now extends to miscarriage and 
stillbirth70, it remains unclear if obstetric conditions predict CVD independent from classical 
risk factors. Awareness of the risk of, in particular, future hypertension and DM remains as 
relevant as before for women with the aforementioned pregnancy-related disorders. 
As for non-obstetric conditions, few new data on the association of polycystic ovary 
syndrome have emerged. Premature menopause, particularly if associated with early 
oophorectomy, remains an important risk factor70 . 
Gender disparities in CVD prevention are age dependent, as shown by an analysis of the 
Treatment of CV Risk in Primary care using Electronic Decision suppOrt (TORPEDO) study 
71. Women attending primary healthcare services in Australia were less likely than men to 
have risk factors measured and recorded such that absolute CVD risk can be assessed. For 
those with, or at high risk of, CVD, the prescription of appropriate preventive medications 
was more frequent in older women, but less frequent in younger women, compared with 
their male counterpart 71. 
Although the percentage of women smokers is lower than men, a recent meta-analysis of 75 
cohort studies (approximately 2.4 million individuals) showed a 25% greater risk of CAD in 
women smokers compared with male smokers (RR, 1.25; 95% CI, 1.12–1.39) 72.  
2.4.2 Ethnicity 
CV risk varies considerably according to ethnicity1. In the recent update on QRISK score 
ethnicity (Indian, Pakistani, Bangladeshi, Chinese, Black African Black Caribbean, Other 
Ethnic group)  leads to meaningful risk reclassification25. 
 
3 HOW TO INTERVENE AT POPULATION LEVEL  
3.1 Healthy Diet 
3.1.1 Governmental restrictions and mandates 
Providing a growing global population with healthy diets from sustainable food systems is 
an immediate challenge. Although global food production of calories has kept pace with 
population growth, more than 820 million people worldwide have insufficient food and 
many more consume low-quality diets that cause micronutrient deficiencies and contribute 
to a substantial rise in the incidence of diet-related obesity and diet-related non-
communicable diseases, including CAD, stroke, and DM. Unhealthy diets pose a greater risk 
to morbidity and mortality than do unsafe sex, and alcohol, drug, and tobacco use 
combined73,74. 
It is predicted that the current generation of children may have a shorter life expectancy than 
their parents due to the high prevalence of obesity and its health consequences. According to 
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the UNICEF and WHO, in Europe 800,000 children suffer from obesity, due to children‘s 
exposure to unhealthy food marketing75.  
A global transformation of the food system is urgently needed.73 Dietary changes from 
current diets to healthy diets are likely to substantially benefit human health, averting about 
10.8 – 11.6 million deaths per year, a reduction of 19.0–23.6%. 
Healthy diets have an appropriate caloric intake and consist of a diversity of plant-based 
foods (including plant protein, i.e. peas, lentils), low amounts of animal source foods, 
unsaturated rather than saturated fats, and small amounts of refined grains, highly 
processed foods, and added sugars73. 
A reduction of intake of sugars and sweeteners and progressive elimination of industrially 
produced trans-fats is recommended 1. 
On 24 April 2019, the European Union Commission adopted a regulation setting a maximum 
limit of trans fat in industrially produced trans fats of 2 grams per 100 grams of fat76. This 
regulation is in line with the Danish regulation and corresponds to what European Heart 
Network (EHN) and other organizations called for. However, the two-year transition period 
till 1 April 2021 is considered too long. 
Evidence-based recommendations on the control of marketing of foods and calorie-rich 
beverages to children which requires governments to protect children‘s health have been set 
up77. On June 2019, the European Commission's science and knowledge service updated the 
document on ―Health Promotion and Disease Prevention‖ highlighted the need for policy 
recommendations to reduce intake of sugars, with a special focus on recommendations for 
children: these recommendation included provision of information to the consumers, to 
make healthy choice more available and to implement financial (dis)incentives such as taxes 
on products with high sugars 78. 
 
3.1.2 Labelling and information 
Independently and coherently formulated criteria for nutrient profiles, nutrition claims and 
front-of-pack logos (e.g. traffic lights, healthy choices, keyholes and Nutriscore) have been 
promoted 79. In particular, since 2017, the logo Nutriscore has been implemented comprising 
negative components (energy, sugar, saturated fat, salt) as well as positive components 
(vegetables, fruits, nuts, fibre and protein) leading to an end score from A  ―best nutritional 
quality‖ to E for the ―least good nutritional quality‖80. This logo has been introduced in 
France and recently in Belgium81. Countries like Spain and Portugal are considering this 
logo. European Consumer organization (BEUC) supports this system, while the EHN 
continues to recommend the traffic light system. In the Netherlands firstly a survey into the 
consumer understanding of different logo‘s will be conducted. 
 
3.2 Physical Activity Promotion 
Physical activity (PA) promotion should be integrated into the settings in which people live, 
work and play, to increase participation.  There are multiple policy opportunities across 
different sectors: schools, business and industry, community recreation, fitness and parks, 
faith based settings, health care, mass media, public health and sports 82.  
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A population-based policy approaches can contribute to reducing inequalities by age, sex 
and socioeconomic status, geographic location and domains of PA, targeting less active in 
PA and should be interconnected with policies actions focused on individually centred 
intervention. The WHO indicates four strategic objectives to create 1) active societies, 2) 
active environments, 3) active people and 4) active systems.  Each objective is an important 
effective component of a population-based response to increasing PA and reducing 
sedentary behaviour, and are achievable through 20 policy actions 83. 
3.2.1 Community-wide campaign. 
Community-wide campaigns that use intensive contact with the majority of the target 
population over time, can increase PA across the population 84. It should involve educational, 
recreational, worksite, primary care and faith-based settings, offering convenient locations 
for reaching different target groups with different strategies. Multicomponent kindergarden 
and school intervention are effective in promoting increased school-based PA 82, 83. 
3.2.2 Environment and Policy Level  
Longer occupational sitting time are significantly associated with higher mortality, while 
higher levels of PA are associated with a reduced risk of cancer and CV death 85. Strong 
evidence shows that point of decision prompts to encourage individuals to make an active 
choice and can increase the use of stairs.84,86 Moderate evidence shows that: 1) built 
environment characteristics and infrastructure that support pedestrian or bicycling transport 
positively affect PA levels among children, adults and older adults; 2) readily usable and safe 
walking and cycling infrastructure and related built environment features are also associated 
with greater amounts of recreational PA among children and adults; 3) access to indoor (gym 
or fitness centres) or outdoor facilities (parks, trails and other green spaces) are associated 
with grater PA among children and adults. To decrease sedentary behaviours, moderate 
evidence suggests that school-based interventions targeting reduction in television viewing 
and other screen-time activities; and worksite interventions including modifications to the 
workstation can have a positive impact.84,86 
 
3.3 Smoking Bans 
Tobacco consumption has been confirmed to be the leading cause of preventable death 
worldwide87.  The risk is high also in never smokers, but who are exposed to exposed to 
second hand smoke: in Greece these individuals exhibited a two-fold elevated 10-year CVD 
risk 88. 
Despite several population-based anti-smoking policies, 28% of the total population across 
Europe is still smoking 89.  
Only high-income European countries showed accelerated decreases in consumption since 
the action plan by the WHO Framework Convention on Tobacco Control (FCTC) on global 
cigarette consumption was ratified by 181 countries. In contrast, low and middle-income 
countries showed increased consumption 90. The difference in effect between the countries 
might be because low and middle-income countries have limited resources to regulate the 
tobacco industry. This should motivate stronger implementation of proven tobacco control 
policies and more forceful responses to the activities of the tobacco industry90. There is very 
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strong scientific evidence about the measures that successfully reduce and prevent tobacco 
use. The most effective strategy is to increase the price of tobacco products87. In addition, 
there are smoke free legislation and policies, marketing restrictions, advertising bans and 
hard-hitting media campaigns, and access to smoking cessation services91. These measures 
should be regulated through robust legislation and rigorous enforcement and have resulted 
in substantial prevalence declines of tobacco use in high-income countries92. A sign towards 
the opposite direction has been given in Austria: the smoking ban which was scheduled to 
begin in May 2018 in all bars and restaurants, was recently overturned by lawmakers from a 
new ruling coalition in the government 93. 
3.3 Air pollution 
Exposure to PM2.5 has been linked to premature mortality, in 70% of the cases due to CV 
causes 94, 95. Even brief exposures to polluted air are associated with MI, stroke, arrhythmias, 
AF, and hospitalization for exacerbation of HF in susceptible individuals 96. There is equally 
strong evidence suggesting that chronic and persistent exposure to air pollution increases the 
progression of atherosclerotic lesions and has adverse effects on BP regulation, peripheral 
thrombosis, endothelial function, and insulin sensitivity. In addition to individual 
susceptibility factors, vulnerability to ambient air pollution is also moderated by 
environmental factors, such as the built environment, noise, ambient temperature, 
neighborhood greenspaces, and proximity to major roadways or co-exposure to other 
pollutants and toxins.97 98 
 
4 HOW TO INTERVENE AT INDIVIDUAL LEVEL 
4.1 Behaviour 
In addition to face-to-face communication, media-based (e.g. telephone, internet, mass 
media) interventions have gained increased attention for CVD prevention. A randomized 
controlled trail on telephone coaching for behaviour change in patients after acute coronary 
syndrome (ACS) has shown significant though modest effects on BMI, waist circumference, 
physical activity, and daily intake of vegetables99. A randomized clinical trial showed the 
effectiveness of a Web‐based health behaviour change support system and group lifestyle 
counselling on body weight loss in overweight and obese subjects 100. 
A systematic review on internet-delivered interventions in patients with CAD has shown 
that personalized, concrete support for behaviour change may have favourable outcomes, 
however, a considerable heterogeneity between studies with respect to the design and 
quality hinder sound conclusions 101. 
 
4.2 Adherence 
CV fixed-dose combination pills, or polypills, may help address the widespread lack of 
access and adherence to proven medicines. Adherence benefits from switching to a polypill 
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resulted in risk factor changes that were at least as good as usual care across a wide variety 
of treatment patterns, including equally potent or more potent regimens 102.  
In addition to face-to-face interventions, there were increasing efforts to evaluate the effects 
of mobile phone-based interventions. With respect to CVD primary prevention, a Cochrane 
systematic review and meta-analysis 103 concluded that there is low-quality and inconclusive 
evidence that mobile phone-based interventions might improve medication adherence 
and/or have favourable effects on outcomes like BP or LDL-cholesterol 103. 
With respect to secondary prevention, a Cochrane Systematic Review104 evaluated mobile 
phone text messaging for patients after acute cardiac events. Due to the heterogeneity of 
methods, populations and outcomes, the authors were unable to perform a meta-analysis. 
Although the authors found favourable effects on medication adherence in 6 out of 7 trials, 
they concluded that there is insufficient evidence to draw conclusions on the effectiveness of 
mobile phone-based interventions in CVD secondary prevention 104. Similar conclusions 
were derived by a systematic review and meta-synthesis of quantitative and qualitative data 
on mobile applications for CVD patients 105. Patients holding implanted device (such as 
Implantable Cardioverter Defibrillator or Cardiac Resynchronisation Sytems) showed little 
interest in receiving dedicated information on the overall management of their disease, 
underlying the insufficient awareness of patients towards the key role of self-control health 
status and the promotion of a healthy lifestyle 106. 
 
4.3 Physical activity and sedentary behaviour. 
PA is associated with beneficial health outcomes. There is an inverse dose-response 
relationship between moderate-vigorous aerobic PA and all-cause and CV mortality and 
incident CVD: CAD, ischaemic stroke and HF 107. Benefit start to accumulate from moving to 
being inactive to perform PA at lower amount, and increases with higher amount of PA 108. 
In healthy adults 150 to 300 minutes a week of moderate-intensity PA or 75 to 150 min of 
vigorous-intensity PA or an equivalent combination thereof (a volume of 500-1000 MET-
minutes per week), reduces the risk of all cause of mortality109. Higher volumes of PA 
through higher intensity, greater frequency or longer duration contributes to risk reduction, 
but greater increases in PA is required to obtain a modest gain in benefit. PA amounts up to 
three to five times the recommendation shows no evidence in mortality risk 107. There is now 
evidence that bouts of any duration, even less than 10 minutes, are effective and counts for 
the daily/weekly volume target of PA84,110. 
There is moderate evidence that high intensity interval training can improve insulin 
sensitivity, BP and body composition similarly to aerobic continuous PA training, especially 
in overweight or obese adult 111. The improvement in risk factors control are more likely to 
occur in adult at greater risk of CVD and DM. There are no universally accepted lengths for 
high intensity period, recovery period or ratio of the two, no universally accepted relative 
intensity at which the high intensity component should be performed. 
There is a strong evidence of a dose-response association between sedentary behavior and all 
cause of mortality, CVD mortality and incident CVD, and type 2 DM84. Individuals who sit 
the most and perform the least of moderate to vigorous PA have the greatest risk of 
mortality, while individual who sit the least and perform the most of moderate to vigorous 
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PA have the lowest risk84,112. Strong evidence for sedentary behavior‘s guideline is still 
lacking. 
The most effective interventions to increase activity are based on theories of behaviour 
change, teaching people skills to incorporate PA in their daily routine and attain an active 
lifestyle. Strong evidence demonstrates that counselling participants to set PA goals and self-
monitoring their progress increase PA in the adult population 110,113.  
Technologies that use computerized information or communication interfaces-based 
approaches can provide virtual coaching and deliver behavioural changes, ―just in time‖ 
personalized advice and support to the users. Wearable activity monitors such as pedometer 
and accelerometers in combination with goals-setting and other behavioural strategies 
provide direct PA feedback and can increase PA levels in general and type 2 DM population 
114. Telephone assisted, web based on internet-based intervention, with educational 
component provide effective remotely guidance to individuals to increase PA. Smartphone 
applications increase PA in children and adolescent 115,116. 
 
4.4 Smoking Cessation: role of electronic cigarette. 
E-cigarettes (electronic cigarettes) are a rapidly changing product class, and are known by 
many different names, including ―e-cigs,‖ ―e-hookahs,‖ ―mods,‖ and ―vape pens‖117. Most e-
cigs contain nicotine whose exposure can harm the developing brain and nicotine exposure 
during adolescence can impact learning, memory, and attention 117. In addition to nicotine, 
the aerosol that users inhale and exhale from e-cig can potentially expose both themselves 
and bystanders to other harmful substances, including heavy metals, volatile organic 
compounds, and ultrafine particles that can be inhaled deeply into the lungs 117. To making 
e-cig more appealing to young people, some of the chemicals used to create certain flavors 
may also have health risks 117. Recently, a new type of e-cig (JUUL) has become increasingly 
popular due to its minimal exhaled aerosol, reduced odor, and small size, making it easy to 
conceal 118, but with a high level of nicotine 119. 
E-cig can be used to deliver other drugs, including marijuana: in 2016, one-third of U.S. 
middle and high school students who ever used e-cig had used marijuana in e-cigarettes 120. 
It may be that e-cigarettes are more effective in promoting nicotine dependence than as an 
aid to smoking cessation.  
  
4.5 Body weight 
There is increasing evidences on the beneficial effect of body weight reduction with caloric 
restriction. A meta-analysis of sixty-three studies showed that each additional kilogram loss 
induced by life-style intervention was associated with 43% lower type 2 DM odds121.  
Caloric restriction without malnutrition leads on increased longevity and delayed onset of 




4.6.1 Fatty acids and carbohydrate intake 
Novel finding have challenged the current guidelines recommendation which restricts 
saturated fat to <10% total fat1. The PURE study of dietary habits in 135,000 people from 18 
countries around the world for 7 years observed that high carbohydrate intake was 
associated with higher risk of total mortality, whereas total fat and individual types of fat 
were related to lower total mortality123. These findings should be considered cautiously since 
about 85% of the fat intake in EU countries is within the highest fat quintile of PURE, where 
the high carbohydrate intake may have been just a proxy for poverty and saturated fat 
consumption was generally low. Finally the negative relationship goes against multiple 
studies1.  
The PURE findings are only partially confirmed by other reports studying the association 
between saturated fats and risk of CAD where the importance of which nutrients saturated 
fats are replaced by is considered: poly unsaturated fats (-25%), mono unsaturated fats (-
15%) and to a lesser extent carbohydrates from whole grains (-9%) reduce CVD risk with 
isocaloric substitution of dietary saturated fat124,125. Also the replacement of animal fats, 
including dairy fat, with vegetable sources of fats and PUFAs may reduce risk of CVD126,127. 
Whether the food matrix may modify the effect of dairy fat on health outcomes warrants 
further investigation. 
4.6.2 Fruit and vegetables 
The PURE study also observed the beneficial effect of increasing consumption of fruit, 
vegetables, and legumes on total and CV mortality: the maximum benefit was seen at three 
to four servings a day (equivalent to 375–500 g/day), with no additional benefit with higher 
intakes123. The benefit from some fruits, vegetables, or legumes was greater if they were 
eaten raw rather than cooked 128. 
4.6.3 Meats 
From both a health point of view as well as environmentally sustainable food production, a 
lower consumption of red meat, especially processed meat, has been usually recommended.  
However, evidences are still controversial. A meta-analysis of 24 RCTs concluded that ≥0.5 
serving/day of red meat did not influence blood lipids, lipoproteins, or BP in comparison 
with <0.5 serving/day 129. A subsequent meta-analysis which included 36 RCTs, only when 
red meat was substituted with high-quality plant foods (i.e. nuts, soy, and legumes) more 
favourable LDL-cholesterol concentrations (-0,2 mmol/l) was observed 130. By reducing 
processed meats, salt intake will be reduced as well. 
4.6.4 Functional foods 
Red yeast rice (RYR) (white rice with the yeast Monascus purpureus) contains monacolins, 
which is chemically identical to lovastatin. Although RYR supplementation is effective in 
reducing LDL-cholesterol, long-term safety and possible adverse effects are not determined. 
Most supplements also contain other ingredients, with unknown effects and interactions131,76. 
The formulation and dosage of RYR is also variable132 rising concerns regarding their 




The relation between salt intake and CVD is debated.  A U-shape association has been 
recently observed in a pooled analysis, which included 133,118 individuals (63,559 with 
hypertension and 69,559 without hypertension), from 49 countries with estimated 24-h 
urinary sodium excretion, from a single morning fasting urine sample133. This finding should 
be confirmed by a more rigorous methodology (eg by 24-hours urine samples complete, 
preferably in several days).  
4.6.6 Alcoholic beverages 
The relation between alcohol consumption and CVD is still controversial, even though the 
evidence base for overall harm is increasing.  
There have been multiple systematic reviews and meta-analyses of the association between 
consumption and aggregated CVD: most have shown that, compared with non-drinking, 
moderate levels of alcohol intake are associated with a lower risk of morbidity and mortality 
from CVD, as well as more favourable CV health profiles in general134. A large-scale study of 
1.93 million adults without CVD at baseline showed that in the group of non-drinkers there 
is an increased risk of CAD, CVD, and all-cause mortality 135.  
There is, however, a growing skepticism around this observation, with recent commentary 
pieces pointing out several methodological shortcomings in the evidence on which the U 
shape is based 136. In a large analysis involving 599,912 current drinkers without previous 
CVD from 19 high-income countries, the threshold for lowest risk of all-cause mortality was 
about 100 g per week. For CVD subtypes, alcohol consumption was roughly linearly 
associated with a higher risk of stroke, CAD excluding MI, HF, fatal hypertensive disease 
and fatal aortic aneurysm. By contrast, increased alcohol consumption was log linearly 
associated with a lower risk of MI 137.  These data support adoption of lower limits of alcohol 
consumption than are recommended in most current guidelines, for example to a maximum 
of 1 glass/portion per day for both men and women. 
 
4.7 Lipid control 
4.7.1 Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition   
The FOURIER trial tested the effect of evolocumab on 27,564 patients with atherosclerotic 
CVD and LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) on a background of statin therapy 138. 
Following treatment with evolocumab, at 48 weeks LDL-C was reduced by 59% compared 
with placebo. After a median follow-up of 2.2 years, evolocumab reduced the risk of the 
primary end point (a composite of CV death, MI, stroke, hospitalization for unstable angina, 
or coronary revascularization) by 15% (p<0.001) and secondary end point (a composite of CV 
death, MI, or stroke) by 20% (p<0.001)138. The effectiveness of evolocumab was independent 
of the baseline LDL-C levels 139.  
The ODYSSEY OUTCOMES study assessed the effect of alirocumab in 18,924 patients with a 
recent ACS, having LDL-C levels ≥70 mg/dL (≥1.8 mmol/L) and receiving statin therapy at a 
high-intensity dose or at the maximum tolerated dose140. At 48 weeks, alirocumab reduced 
LDL-C levels by 54.7%; after a median follow-up of 2.8 years, the risk of a composite primary 
end-point event (death from CAD, nonfatal MI, fatal or nonfatal, ischemic stroke, or unstable 
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angina requiring hospitalization) was reduced by 15% (p<0.001), with a greater absolute 
benefit among patients with higher baseline LDL-C levels140. 
In both studies no increase in new-onset DM nor worsening of glycaemic parameters were 
observed, nor was there evidence of an adverse effect on cognitive function or risk of cancer. 
The results of these two trials support a clinical benefit from LDL-C lowering beyond that 
obtained with statin therapy in high and very high risk patients and lower LDL-C targets 
adopted by the 2019 ESC guidelines 64. However data on long term safety and total survival 
are still awaited.  
Cost-effectiveness can be a critical issue in the context of prescription of PCSK9-inhibitors141 
and a selective adoption to very high‐risk CVD patients to reduce the overall budgetary 
impact of PCSK9i treatment has been advised 142,143.  
4.7.2 Omega-3 Fatty Acids 
Patients with elevated triglyceride (TG) levels are at increased risk for ischaemic events; the 
REDUCE-IT trial evaluated the effect of icosapent ethyl (a highly purified eicosapentaenoic 
acid ethyl ester, 4 g daily) in 8,179 patients with established CVD, under statin therapy and 
with high fasting TG levels (135-499 mg/dL) 144.  After a mean follow-up of 4.9 years, the risk 
of primary endpoint (a composite of CV death, nonfatal MI, nonfatal stroke, coronary 
revascularization, or unstable angina) was reduced by 25% and secondary endpoint (a 
composite of CV death, nonfatal myocardial infarction, or nonfatal stroke) by 26%144.  
These results should be contrasted against the background of other recent findings. A meta-
analysis of 10 randomized trials involving 78,000 patients did not show that the groups that 
received n–3 fatty acids had a lower risk of major adverse CV events than those receiving 
placebo 145, although most trials were not confined to subjects with raised triglyceride levels, 
nor did ASCEND (A Study of Cardiovascular Events in Diabetes), which tested 1-g capsules 
containing 840 mg of marine n–3 fatty acids daily in patients with type 2 DM146. In addition, 
the results of the Vitamin D and Omega-3 Trial (VITAL), a primary-prevention trial 
involving more than 25,000 participants, did not show a lower incidence of the primary CV 
composite outcome of MI, stroke, or CV death in either arm 147. 
More data are needed to clarify the benefit of this class of drugs. also in higher dosage in CV 
event reduction.  
 
4.8 Diabetes Mellitus 
Multiple positive trials demonstrating superiority of novel class of DM agents for either CV 
or renal outcomes have emerged. In some cases, total or CV mortality was reduced, and 
positive results were also seen for the prevention of HF.  Such positive trials come either 
from the Sodium-glucose co-transporter-2 (SGLT2) inhibitor class (empagliflozin, 
dapagliflozin or canagliflozin), as recently summarized in a meta-analysis 148, or the 
glucagon-like peptide 1 (GLP-1) receptor agonist class of drugs (liraglutide, semaglutide, 
albiglutide, dulglutide) likewise recently summarised for drugs 149. The outcome benefits for 
most of the drugs in each class outweigh potential harms and side effects and both classes 
cause weight loss and reductions in BP without increasing hypoglycaemia rates. 
Consequently, the use of such agents in those with existing CVD has been promoted in many 
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guidelines, although uptake has been modest150. Notably, the prevention of HF or prevention 
of meaningful renal outcomes seems to occur to broadly similar extents with SGLT2 
inhibitors whether patients have existing CVD or multiple risk factors 148. Thus, those 
without existing CVD but at elevated risk of HF or renal progression would stand to benefit 
from earlier SGLT2 inhibitor use.  Such guidance fits with an increasing focus on prevention 
of HF in DM. The outcome benefits of both classes seem to be largely independent of their 
effects on glucose levels per se.  This is in keeping with the recent findings from the DAPA-
HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trail: among 
patients with HF and a reduced ejection fraction, the risk of worsening HF or death from CV 
causes was lower among those who received dapagliflozin than among those who received 
placebo, regardless of the presence or absence of diabetes 151.  
4.9 Hypertension 
The SPRINT trial introduced the ―unobserved‖ BP measurement, a method that it is 
recommended in the Canadian Guidelines 152, but that it is difficult to apply in many 
healthcare facilities and produces BP levels that are lower than office measures on which 
many epidemiological studies and previous intervention trials have been based. 
Furthermore, some SPRINT participants had medication reduced to allow them to 
participate, which complicates interpretation. Out-of office BP measurement is upgraded as 
the best method to diagnose and control hypertension. Wider use of out-of-office BP 
measurement with ambulatory monitoring (ABPM) and/or Home BP measurement (HBPM) 
are considered an option to confirm the diagnosis of hypertension, detect white coat and 
masked hypertension, and monitor BP control is today recommended58. 
The second recommendation includes a change in the strategy to improve BP control. Two 
drug combination therapy for the initial treatment of most people with hypertension, 
preferred in single pill, is today recommended. Simplified drug-treatment algorithms are 
recommended with the preferred use of an angiotensin-converting enzyme inhibitor (ACE) 
inhibitor or angiotensin receptor blocker (ARB) combined with a calcium channel blocker 
or/and a thiazide/thiazide-like diuretic as the core treatment strategy for most patients, with 
beta-blockers used for specific indications. Monotherapy is recommended for subjects with 
stage 1 hypertension with low risk (particularly if SBP <150 mmHg) or in very old (>80 
years) or frailer subjects 58. 
The third recommendation corresponds to when to treat and goals to be achieved. Overall 
there is a less conservative treatment of BP and the newly introduced target BP ranges for 
treated patients, to better identify the recommended BP target and lower safety boundaries 
for treated BP, according to a patient‘s age and specific comorbidities. Lower BP thresholds 
and treatment targets for older patients are recommended with emphasis on considerations 
of biological rather than chronological age (i.e. the importance of frailty, independence, and 
the tolerability of treatment). In this regard, treatment should never be denied or withdrawn 
on the basis of age, provided that treatment is tolerated58. 
Guidelines also recommended drug treatment: a) to subjects with white-coat hypertension if 
evidence of hypertension multi organ damage or in whom CV risk is high or very high is 
present; b) to subjects in high-normal BP when their CV risk is very high due to established 
CVD, mainly coronary heart disease58. 
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Finally, strong emphasis on the importance of evaluating treatment adherence as a major 
cause of poor BP control is today a key issue, as well as the key role for dieticians, nurses and 
pharmacists in the longer-term management of hypertension. Their role in the education, 
support, and follow-up of treated hypertensive patients is relevant as part of the overall 
strategy to improve BP control58. 
Unfortunately, not all the gaps pointed out in the ESC CVD prevention guidelines are solved 
today.  What still unanswered is the optimal out-of-office (home and ambulatory) BP targets, 
and does treatment strategies based on control of out-of-office BP provide an advantage over 
strategies based on conventional (office) BP control?  
 
4.10 Antiplatelet therapy 
New evidence supports the current recommendation against aspirin use in primary 
prevention1. Recent meta-analyses including respectively 11 and 15 trials with >155,000 
individuals each without history of atherosclerotic disease demonstrated that aspirin did not 
affect  all-cause mortality or CV death or no CV death in the primary prevention setting153. 
This was further confirmed by sequential analysis, which also suggested the futility of 
conducting further trials to assess a benefit of aspirin on all-cause mortality154. 
The lack of benefit was evident even in people with DM and patients with high CV risk (i.e. 
10-year risk >7.5%). The use of aspirin for primary prevention in patients with DM increases 
the risk of total bleeding without reducing the risk of major adverse CV outcomes 155. 
 
4.11 Psychosocial factor 
The current Guideline 1 recommends treatment of psychosocial risk factors via multimodal 
behavioral interventions, psychotherapy, medication or collaborative care, in order to 
counteract psychosocial stress, depression and anxiety, to facilitate behaviour change and to 
improve quality of life and prognosis in patients with established CVD and patients at high 
CVD risk, when the psychosocial risk factor worsens classical risk factors.  
A recent meta-analysis on psychological interventions in addition to exercise-based CR 
compared to exercise-based CR alone in patients with CAD156 has shown a trend for a 
reduction of depressive symptoms and cardiac morbidity, but no additional impact on 
anxiety, quality of life and CV or total mortality 156. Hence, considering the low to moderate 
quality and high methodological heterogeneity of available studies, there is considerable 
uncertainty under which conditions psychological interventions in addition to exercise-based 
CR exert their optimal effects 156. 
Another meta-analysis showed the efficacy of cognitive psychotherapy for reducing 
psychological symptoms in patients with CVD and significant symptoms of depression and 
anxiety 157, but there was no effect on CV events 157. But, a recent trial, for the first time, has 
shown a favorable effect of antidepressant medication on long-term cardiac outcomes 158. In 
patients with ACS and minor/major depression, the effectiveness of therapy with a Selective 
Serotonin Reuptake Inhibitors (SSRI, escitalopram) on depression and anxiety resulted in a 
significant reduction of major adverse cardiac events (MACE) after 8.1 years (HR 0.68, 95% 
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CI, 0.49-0.96; p=0.03)158. Thus, treatment with SSRIs may improve subjective wellbeing and 
prognosis in depressed patients with CAD, but confirmation by additional trials is needed. 
 
 
5 DISEASE SPECIFIC INTERVENTION 
5.1 Atrial fibrillation 
The focused update on CV prevention in patients with AF is mainly based on the topic of 
anticoagulation, because of the approval of new medications and the emerge of new 
strategies after ACS.  
Based on the four major randomized clinical trials comparing non–vitamin K oral 
anticoagulants (NOACs) with warfarin (vitamin K antagonist, VKA)159,160,161,162, there is now 
consistent evidence of at least noninferiority for the combined endpoint of stroke or systemic 
embolism. When combined with a superior safety profile, NOAC are now recommended as 
first line therapy for eligible patients. 
In patients with AF and ACS managed by percutaneous coronary intervention (PCI), 
recommended strategies need to incorporate recent evidence from PIONEER AF-PCI (An 
Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies 
of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in 
Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention) 163 and 
RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran 
versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial Fibrillation 
Undergoing Percutaneous Coronary Intervention) 164, considering rivaroxaban and 
dabigatran options for anticoagulants in this patient population. PIONEER AF-PCI 
randomized patients to low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 
12 months; very-low-dose rivaroxaban (2.5 mg twice daily) plus dual anti-platelet therapy 
(DAPT) for 1, 6, or 12 months; or standard therapy with a dose-adjusted VKA (once daily) 
plus DAPT for 1, 6, or 12 months. The rates of thromboembolic events (death from CV 
causes, ACS, or stroke) were similar in the three groups, while significant bleeding was 
lower in the two rivaroxaban groups. RE-DUAL PCI randomized patients to receive double 
therapy with dabigatran (110 mg twice daily) plus either clopidogrel or ticagrelor, double 
therapy with dabigatran (150 mg twice daily) plus either clopidogrel or ticagrelor, or triple 
therapy with warfarin plus aspirin (≤100 mg daily) and either clopidogrel or ticagrelor. With 
respect to the composite efficacy end point of thromboembolic events (MI, stroke, or 
systemic embolism), death, or unplanned revascularization dabigatran-based dual therapy 
was non-inferior to VKA-based triple therapy. Dual therapy with dabigatran also reduced 
bleeding complications as compared to conventional triple therapy. Also a non inferiority for 
bleeding of an edoxaban-based regimen compared with the VKA-based regimen, without 
significant differences in ischaemic events in patients with AF who had PCI was observed in 
the ENTRUST-AF PCI (Edoxaban Treatment Versus Vitamin K Antagonist in Patients With 
Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) trial 165.  
Taken together, these two studies seem to orient clinical practice towards an increasing use 
of dual therapy (consisting of a NOAC plus clopidogrel, which was the most common P2Y12 
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inhibitor used), even though current recommendations consider NOAC-based dual therapy 
in only a subset of patients at increased risk of bleeding 166.  
 
5.2 Coronary Artery Disease 
In CAD patients, secondary prevention should start as soon as possible, and physicians in 
general practice are the key person to initiate and coordinate intervention and provide long-
term follow-up. A systematic approach is recommended to risk assessment. Specialized 
prevention programmes should be delivered as cardiac rehabilitation167 or other structured, 
physician-led prevention programmes for all patients with CVD or at high risk for CVD. The 
structure, length and type of programme offered differs widely by country, affected by 
national guidelines and standards, legislation and payment factors.  
Despite significant improvements in the management of patients presenting with ACS, 
secondary prevention remains challenging 168. The implementation of pharmacological and 
non-pharmacological interventions is 169.: Proper utilization of and adherence to evidence-
based treatment strategies and interventions has to be the priority after ACS in order to 
improve long-term outcomes. It is essential to identify health system-related difficulties and 
weaknesses in the management and support of secondary prevention post-ACS discharge 170.  
 
5.3 Heart Failure  
5 3 1 Biomarkers 
Plasma biomarkers are useful tools in the diagnosis and prognosis of HF. Whereas cardiac-
specific biomarkers, including natriuretic peptides (ANP and BNP) and high sensitivity 
troponins (hsTn), are widely used in clinical practice, other biomarkers have not yet proven 
their utility 171. Thus, some plasma biomarkers have the potential to provide information 
about specific processes (e.g. cardiac strain, interstitial/replacement fibrosis, endothelial 
dysfunction, and pathological hypertrophic processes) that drive cardiac dysfunction in the 
individual HF patient 172 and they could be used to improve and guide medical therapy 173. 
5 3 2 Exercise training  
New meta-analysis174 and the Cochrane meta-analysis175 involved 44 studies that included 
5783 people with HFrEF, had findings consistent with those of the previous (2014) version of 
Cochrane Review: significant reductions of overall hospital admissions, as well as of HF 
admissions.  These findings have been recently confirmed by the CROS-HF meta-analysis 
and review 176.  
Further evidence is needed to better show the effects of exercise rehabilitation among 
traditionally less represented HF patient groups including older, female, people with HFpEF 
(currently under investigation) as well as the impact of and alternative delivery settings 
including home- and using technology-based programmes. 
5 3 3 Telemonitoring  
Recent Cochrane review identified 25 relevant trials and found that telemonitoring reduced 
all-cause mortality by about 20% and HF hospitalisation by about 30% 177 The beneficial 
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effects have been confirmed by the TIM-HF2 trial which demonstrated that remote 
telemonitoring including home assessment of weight, BP, ECG and general health status in 
the context of a 24/7 support system, reduced the proportion of days lost due to unplanned 
CV (mainly HF) hospitalizations or death (p=0.046) 178.  
 
5.4 Cerebrovascular disease 
Despite advances in earlier diagnosis, reperfusive strategies, and aggressive management of 
risk factors, stroke remains a leading cause of death and long-term disability worldwide. 
Recently, the POINT study179 compared short-term (three months) DAPT based on aspirin 
and clopidogrel with a single antiplatelet regimen in patients with minor stroke and high-
risk Transient Ischemic Attack, showing a reduction in recurrent stroke in the DAPT group 
at 90 days and a higher risk of major bleeding than aspirin alone: HR for ischemic events 
(mostly occurring in the first week after the index event) was 0.75 [95% CI 0.59 to 0.95], while 
90 days prevalence of major haemorrhage was 0.9% in the DAPT group versus 0.4% in the 
aspirin alone group [HR 2.32; 95% CI 1.10 to 4.87]. In this population generally considered as 
having lower risk (as compared to patients with AF in whom anticoagulation is mandatory, 
or patients with severe extracranial carotid disease who might benefit from endarterectomy 
or stenting), novel evidence confirmed the difficulty to obtain clear net benefit by adopting 
combination antiplatelet therapy.  
Recent acquisitions are also targeted on risk reduction of future stroke and dementia in 
subjects with silent cerebrovascular disease (SCD), a common incidental finding on cerebral 
brain imaging defined as the presence of silent brain infarcts, magnetic resonance imaging 
white matter hyperintensities of presumed vascular origin and cerebral microbleeds. In 
clinical practice, magnetic resonance imaging is preferred to computed tomography (for the 
diagnosis of SCD, as it allows to detect chronic microbleeds. As in the case of primary and 
secondary prevention of stroke, patients with SCD also need intensive evaluation and 
modification of vascular risk factors, including hypertension, DM, dyslipidemia, cigarette 
smoking, and physical inactivity 180.  
 
5.5 Peripheral artery disease 
Patients with peripheral arterial disease (PAD) have heightened risk of CV morbidity and 
mortality, being unfortunately often under-recognized and under-treated.  
Exercise training combined with revascularization procedures, is the cornerstone in the 
treatment, and prevention of progression in PAD 181,182. 
Antithrombotic therapy based on combination therapies may play important role in 
prevention of death, ischaemic CV and limb events in patients with lower extremities PAD. 
In the COMPASS trial183, low dose (2.5 mg twice a day) of NOAC rivaroxaban plus aspirin 
(100 mg once a day) – as compared to aspirin alone - showed to reduce the composite 
endpoint of CV death, MI, or stroke (HR 0.72, 95% CI 0.57-0.90, p=0.0047), and major adverse 
limb events including major amputation (HR 0.54, 95% CI 0.35-0.82, p=0.0037) among 
patients with previous peripheral bypass surgery or angioplasty, limb or foot amputation, 
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intermittent claudication, carotid or CAD with an ABI of less than 0.90. However 
rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin 
alone group (HR 1.61, 95% CI 1.12-2.31, p=0.0089), which was mainly gastrointestinal. The 
cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with 
peripheral or carotid artery disease has been assessed by in a high-income country only 
(Australian).184  
In the PEGASUS-TIMI 54 randomized trial185 the addition of ticagrelor (90 mg b.i.d. or 60 mg 
b.i.d.) to aspirin in a subgroup of PAD patients with a history of MI (one to three years 
earlier) was associated with reduced risk of CV and limb events at the expense of increased 
major bleeding. The absolute risk reduction was 4.1% (number needed to treat: 25) and the 
60-mg dose had particularly favorable outcomes for CV and all-cause mortality. According 
to novel evidence, the use of combined antithrombotic therapies could be now advocated for 
secondary prevention in symptomatic PAD, even though their adoption needs to be tailored 
according to individual thrombotic and bleeding risk.  
The pivotal role of exercise training has been highlighted in systemic reviews of randomized 
controlled trial where the combination of physical intervention and lower limb 
revascularization lead to increase in pain-free (mean difference range 38-408 m) and in 
maximal walking distances (range 82-321 m) 181.  
Another meta-analysis confirmed the higher efficacy of  the combination of exercise training 
and revascularisaion in improving total walking distance, ABI, and reducing the risk of 
future revascularization or amputation 182. 
 
 
6. SETTINGS AND AUDIT 
6.1 Clinical settings  
The role of primary care and community services in CV prevention remains essential, both in 
identification of high-risk individuals and in providing interventions.  Population screening 
via Health Checks in England has shown that the proportion of individuals attending was 
higher among older people, those with CVD family history and those in economically 
deprived areas. Data on impact are limited but have shown a small increase in disease 
detection, statin and anti-hypertensive prescriptions and a small decrease in modelled CVD 
risk186.  A systematic review of 31 studies using multiple health behaviour changes in 
primary care to reduce CV risk in people without established CVD found a modest, 
statistically significant effect on individual behaviours and overall CV risk 187.  
A meta-analysis of prospective controlled cohort studies (pCCS) and retrospective controlled 
cohort studies (rCCS) published since 1995 confirmed the efficacy of cardiac rehabilitation 
(CR) on cardiac prognosis even in the era of statin therapy and acute revascularisations188. 
CR after ACS event and coronary artery bypass graft (CABG) intervention was significantly 
associated with reduced mortality (HR pCCSs 0.37, 95% CI 0.20-0.69; rCCSs 0.64, 95% CI 
0.49-0.840.37 – 0.64), but the heterogeneity of study designs and CR programmes highlight 





Engaging CV prevention more widely with at–risk individuals and patients could be 
enhanced through eHealth interventions. To improve CR uptake and delivery, e-health 
(telemedicine) technology has been shown to be cost-effective in Belgium 189.  In a systematic 
review of 30 trials, telehealth as an adjunct or an alternative to rehabilitation or usual care 
achieved improved outcomes in recurrent cardiac events, total cholesterol, LDL and 
smoking. 190  
The use of mobile apps continues to grow.  A review of 10 studies (n = 607 patients) found 
that patients found some features appealing: behavioural tracking, self-monitoring, 
education, managing provider communication, and flexible, customisable options.  The 
studies found variable results in effectiveness in risk factor control and self-management105.  
A major challenge for eHealth interventions is their variability, and need to determine the 
features, components, frequency and duration of contact that are most effective for changing 
behavior and decreasing CVD risk.    
 
 
6.3 How to monitor preventive activities: Standard of performance  
The latest 2016 Guidelines1 recommends to monitor the process of CVD prevention activities 
delivery and outcomes to improve implementation quality of care in clinical practice. The 
development of standards of performance involves the identification of a set of measures, 
targeting a specific patient population observed over a particular time period. These 
measures should be specifically suitable for public and external reporting, providing an 
indication of quality. The EAPC of the ESC is undergoing to a Quality of care program 
aiming to develop and implement an accreditation of clinical centres providing primary 
prevention, secondary prevention and rehabilitation, and sports cardiology, to be applied in 
ESC related countries 191. 
The ACC/AHA reviewed updated the Clinical Performance and Quality measures for 
Cardiac Rehabilitation (CR)192, considering the following CR Performance Measures (PM): 
1 CR Patient Referral (Inpatient Setting): Percentage of patients, hospitalized with 
qualifying event/diagnosis for CR in previous 12 months referred to outpatient CR program. 
2 Exercise Training Referral for HF (Inpatient Setting) Percentage of patients, hospitalized 
with primary diagnosis of HF with reduced ejection fraction (HFrEF) in previous 12 months, 
referred for exercise training, typically delivered in the setting of outpatient CR program 
3 CR Patient Referral (Outpatient Setting) Percentage of patients, in outpatient setting, who 
in the previous 12 months had a qualifying event/diagnosis for CR and did not participate in 
CR program, but are to be referred to a program 
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4 Exercise Training Referral for HF (Outpatient Setting) Percentage of patients, in outpatient 
setting who in the previous 12 months,  had a new HFrEF event or exacerbation, and have 
not participated in an exercise training program, but are to be referred for exercise training.  
5a CR Enrolment–Claims Based (Outpatient Provider) Percentage of patients, with 
qualifying event/diagnosis for CR  who attend at least 1 session in a CR program 
5b CR Enrolment–Registry/Electronic Health Records Based (Inpatient Provider)  
Percentage of patients with qualifying event/diagnosis for CR who attend at least 1 session 
in a CR program. 
Every CV Prevention or CR program should formally be submitted to regular audits, which 
should include the collection of data to meet the purpose of monitoring prevention and 
rehabilitation service resources193. 
 
 
7 GAPS IN KNOWLEDGE 
 
Unfortunately, not all the gaps pointed out in the ESC CVD prevention guidelines are solved 
today.   
 The need for a revaluation and recalibration of the current risk scores  
 Evidence, cost-effectiveness and potential harm of larger-scale use of CAC scoring for 
refinement of risk stratification  
 The role of cardiac biomarkers (i.e. natriuretic peptide and cardiac troponin blood 
concentration) in risk stratification  
 There is still no evidence of cost-effectiveness of application of CV genetic risk score 
testing in clinical practice, such as targeting statin therapy in individuals at low-to-
moderate CV risk 
 The use of CT coronary angiography as a risk stratification tool in asymptomatic 
individuals is not supported by data   
 Refinement of the screening items with established psychometric questionnaires is 
required. 
 Strong evidences of the effectiveness of influenza vaccination in primary prevention of 
CVD are still lacking. 
 Whether periodontal therapy can prevent the recurrence of CVD in the long term in 
patients with chronic periodontitis. No evidence on primary prevention was found. 
 The magnitude of the problem of CVD in young adults and to elucidate treatable risk 
factors that underlie the observed increasing rates of CVDs in this population 
 The decision to initiate primary prevention with statins in people older than 75 years of 
age cannot be based directly on randomised clinical trials evidence 
 Thus limited evidence is available on therapy for primary prevention of CVDs in very 
elderly and frail individuals. 
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 E-cigarettes may be more effective in promoting nicotine dependence than as an aid to 
smoking cessation. 
 Evidences on the benefit in terms of increased longevity and delayed onset of age-
associated disorders of caloric restriction without malnutrition in humans 
 The relation between alcohol consumption and CVD is still controversial, even though 
the evidence base for overall harm is increasing.  
 The U-shape association between salt intake and CVD is debated.   
 The clinical benefit from LDL-C lowering beyond that obtained with statin therapy in 
high and very high risk patients has been put forward, although data on long term safety 
and total survival are still awaited. 
 To clarify the benefit of Omega-3 Fatty Acids also in higher dosage in CV event 
reduction. 
 The optimal out-of-office (home and ambulatory) BP targets, and whether treatment 
strategies based on control of out-of-office BP provide an advantage over strategies based 
on conventional (office) BP control 
 Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people 
with peripheral or carotid artery disease has been assessed by in a high-income country 
only  
 Which conditions psychological interventions in addition to exercise-based CR exert their 
optimal effects 
 Treatment with SSRIs may improve subjective wellbeing and prognosis in depressed 
patients with CAD, but confirmation by additional trials is needed 
 The heterogeneity of study designs and CR programmes highlights the need for defining 
internationally accepted standards in CR, including lifestyle changes 
 Further evidence is needed to better show the effects of exercise rehabilitation among 
traditionally less represented HF patient groups including older, female, people with 
HFpEF (currently under investigation) as well as the impact of and alternative delivery 
settings including home- and using technology-based programmes. 
 A major challenge for eHealth interventions is their variability, and there need to 
determine the features, components, frequency and duration of contact that are most 





ABI  ankle–brachial (blood pressure) index 
ABPM  ambulatory blood pressure monitoring 
ACC  American College of Cardiology 
ACE-I  angiotensin-converting enzyme inhibitor 
ACS  acute coronary syndromes 
AF  atrial fibrillation 
AHA  American Heart Association 
AHI  apnea–hypopnea index 
AMI  acute myocardial infarction 
apoA1  apolipoprotein A1  
apoB  apolipoprotein B 
ARB  angiotensin receptor blocker 
BEUC  Bureau Européen des Unions de Consummateurs 
BMI  body mass index (weight (kg)/height (m2)) 
BNP  B-type natriuretic peptide  
BP  blood pressure 
CABG  coronary artery bypass graft 
CAC  coronary artery calcium  
CAD  coronary artery disease 
CI  confidence interval  
CKD  chronic kidney disease 
CPAP  continuous positive airway pressure 
CR  cardiac rehabilitation 
CSA  Central sleep apnea 
CSR  Cheyne-Stokes Respiration 
CT  computed tomography 
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CV  cardiovascular 
CVD  cardiovascular disease 
DALYs   disability-adjusted life years 
DAPT  dual anti-platelet therapy 
DASH  Dietary Approaches to Stop Hypertension 
DBP  diastolic blood pressure 
DCCT  Diabetes Control and Complications Trial 
DHA  docosahexaenoic acid 
DM  diabetes mellitus 
e-cig  E-cigarettes 
ED  erectile dysfunction 
EHN  European Heart Network 
ESC  European Society of Cardiology 
EU  European Union 
GLP-1  glucagon-like peptide 1 
HBPM  home blood pressure measurements 
HF heart failure 
HR hazard ratio 
hsCRP  high-sensitivity C-reactive protein 
IHD ischaemic heart disease 
JTF Joint Task Force 
LDL-C  low-density lipoprotein cholesterol 
Lp(a) lipoprotein(a)  
MACE major adverse cardiac events 
MI myocardial infarction 
NOAC non–vitamin K oral anticoagulants 
OSA obstructive sleep apnoea 
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OR odds ratio 
PA physical activity 
PAD peripheral artery disease 
PCI percutaneous coronary intervention 
PCSK9 proprotein convertase subtilisin/kexin type 9 
RA rheumatoid arthritis 
SCD silent cerebrovascular disease 
SGLT2 Sodium-glucose co-transporter-2 
SSRI Selective Serotonin Reuptake Inhibitors 
TG triglycerides 
VKA vitamin K antagonist 
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